Raymond James Trust N.A. reduced its stake in shares of CVS Health Corporation (NYSE:CVS) by 1.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 97,084 shares of the pharmacy operator’s stock after selling 1,715 shares during the period. CVS Health Corporation comprises 0.7% of Raymond James Trust N.A.’s portfolio, making the stock its 29th largest position. Raymond James Trust N.A.’s holdings in CVS Health Corporation were worth $8,640,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of CVS. Dynamic Advisors Solutions LLC raised its stake in CVS Health Corporation by 9.8% in the third quarter. Dynamic Advisors Solutions LLC now owns 3,373 shares of the pharmacy operator’s stock worth $300,000 after buying an additional 300 shares during the period. Gillespie Robinson & Grimm Inc. raised its stake in CVS Health Corporation by 3.3% in the third quarter. Gillespie Robinson & Grimm Inc. now owns 293,493 shares of the pharmacy operator’s stock worth $25,484,000 after buying an additional 9,420 shares during the period. Fisher Asset Management LLC raised its stake in CVS Health Corporation by 2.3% in the third quarter. Fisher Asset Management LLC now owns 132,741 shares of the pharmacy operator’s stock worth $11,813,000 after buying an additional 2,958 shares during the period. Naples Global Advisors LLC raised its stake in CVS Health Corporation by 5.7% in the third quarter. Naples Global Advisors LLC now owns 2,887 shares of the pharmacy operator’s stock worth $257,000 after buying an additional 155 shares during the period. Finally, Gofen & Glossberg LLC IL raised its stake in CVS Health Corporation by 1.8% in the third quarter. Gofen & Glossberg LLC IL now owns 59,740 shares of the pharmacy operator’s stock worth $5,316,000 after buying an additional 1,058 shares during the period. 80.44% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for CVS Health Corporation (NYSE:CVS)

CVS Health Corporation (NYSE:CVS) traded up 1.390% during midday trading on Wednesday, hitting $76.935. 7,303,680 shares of the stock traded hands. CVS Health Corporation has a 52-week low of $69.30 and a 52-week high of $106.67. The firm’s 50-day moving average is $81.47 and its 200-day moving average is $91.44. The company has a market cap of $82.05 billion, a price-to-earnings ratio of 16.488 and a beta of 0.88.

CVS Health Corporation (NYSE:CVS) last announced its quarterly earnings results on Tuesday, November 8th. The pharmacy operator reported $1.64 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.07. CVS Health Corporation had a net margin of 2.96% and a return on equity of 17.18%. The company had revenue of $44.60 billion for the quarter, compared to analysts’ expectations of $45.29 billion. During the same quarter in the previous year, the business posted $1.28 earnings per share. CVS Health Corporation’s quarterly revenue was up 15.5% on a year-over-year basis. Analysts predict that CVS Health Corporation will post $5.81 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, November 3rd. Investors of record on Monday, October 24th were given a $0.425 dividend. This represents a $1.70 annualized dividend and a yield of 2.24%. The ex-dividend date was Thursday, October 20th. CVS Health Corporation’s dividend payout ratio is presently 36.40%.

WARNING: This piece was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2016/11/30/raymond-james-trust-n-a-decreases-position-in-cvs-health-corporation-cvs.html.

A number of analysts recently weighed in on CVS shares. Credit Suisse Group AG reaffirmed an “outperform” rating and set a $110.00 target price (down previously from $115.00) on shares of CVS Health Corporation in a report on Tuesday, October 4th. Robert W. Baird decreased their target price on shares of CVS Health Corporation from $114.00 to $104.00 and set an “outperform” rating on the stock in a report on Monday, October 3rd. Leerink Swann reissued an “outperform” rating and issued a $105.00 price target (down previously from $110.00) on shares of CVS Health Corporation in a report on Sunday, October 2nd. Vetr raised shares of CVS Health Corporation from a “buy” rating to a “strong-buy” rating and set a $98.36 price target on the stock in a report on Monday, October 24th. Finally, Mizuho reissued a “buy” rating and issued a $111.00 price target on shares of CVS Health Corporation in a report on Friday, September 30th. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $106.24.

About CVS Health Corporation

CVS Health Corporation, together with its subsidiaries (CVS Health), is a pharmacy company. The Company operates through three business segments: Pharmacy Services, Retail/LTC and Corporate. The Company offers a range of products and services, such as advising patients on their medications at its CVS Pharmacy locations, introducing programs to help control costs for its clients at CVS Caremark, how care is delivered to its patients with conditions through CVS Specialty, pharmacy care for the senior community through Omnicare.

5 Day Chart for NYSE:CVS

Receive News & Stock Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related stocks with our FREE daily email newsletter.